Navigation Links
Arthritis drug could help beat melanoma skin cancer
Date:3/23/2011

A breakthrough discovery by the University of East Anglia (UEA) and Children's Hospital Boston promises an effective new treatment for one of the deadliest forms of cancer.

Reporting in the March 24 edition (front cover story) of the journal Nature, the researchers found that leflunomide - a drug commonly used to treat rheumatoid arthritis also inhibits the growth of malignant melanoma.

Melanoma is a cancer of the pigment cells in our skin. It is the most aggressive form of skin cancer and, unlike most other cancers, incidence of the disease is increasing. More than 10,000 patients in the UK are diagnosed with melanoma each year. If caught early, surgery can be used to safely remove the tumour but the chances of survival for patients whose tumour is already spreading are very low. Around 2000 people a year in the UK die from malignant melanoma because the cancer has returned after being removed surgically.

UEA scientists Dr Grant Wheeler and Dr Matt Tomlinson conducted a rigorous screen of thousands of compounds, looking for those that affect the development of pigment cells in tadpoles. (See: http://www.uea.ac.uk/mac/comm/media/press/2009/jan/tadpoles). They identified a number of compounds that affected pigment cell development and have now shown with their US collaborators at Children's Hospital Boston that leflunomide significantly restricts tumour growth in mouse models.

And when leflunomide is used in combination with PLX4720, a promising new melanoma therapy currently undergoing clinical trials, the effect was even more powerful leading to almost complete block of tumour growth.

The next stage is for clinical trials to be conducted into the use of leflunomide to fight melanoma. Because leflunomide is already licensed to treat arthritis, this process should be faster than usual and a new treatment for melanoma could be available
'/>"/>

Contact: Simon Dunford
s.dunford@uea.ac.uk
44-160-359-2203
University of East Anglia
Source:Eurekalert

Page: 1 2

Related biology technology :

1. Alder Biopharmaceuticals Announces That Data From Multiple Studies of ALD518 (BMS945429), an Investigational Antibody Therapeutic in Rheumatoid Arthritis Patients, to be Presented at Annual Meeting of the American College of Rheumatology
2. Tarsa Therapeutics and Unigene Present Preclinical Data Suggesting Calcitonin May Have Utility in Combination Therapy for the Treatment of Osteoarthritis
3. Data Published Today Reveal That Novel Oral Therapy Fostamatinib Demonstrates Positive Response in Rheumatoid Arthritis Patients
4. Lubricating the knee cartilage after ACL injury may prevent osteoarthritis
5. Viron reports positive proof of concept results in arthritis for its VT-346 anti-TNF therapeutic
6. Viron granted U.S. Patents for Organ Transplant and Arthritis Drug Candidates
7. Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas
8. New Technology Now Available In Canada For Osteoarthritis
9. New SIMPONI(TM) Data Show Inhibition of Joint Damage in Patients With Rheumatoid Arthritis and Psoriatic Arthritis
10. New SIMPONI(TM) Data Show Long-Term Efficacy in Treatment of Rheumatoid Arthritis
11. Lubris, Biomodels Report on Potential New Therapy for Osteoarthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... CA (PRWEB) July 10, 2014 Senior ... institutions and professional associations, addressed the challenges of “Reducing ... Medical Device Industries” through strategic sourcing. Describing the partnership ... with the Supply Chain Management Institute ( SCMI) ... event on June 24 at the Kroc Institute of ...
(Date:7/10/2014)... , July 10, 2014 Research ... addition of the "International Photonic Integrated Circuit ... Forecasts to 2019" report to their offering. ... The concept of photonic integration traces its ... century. The promise of photonic integration went unexplored ...
(Date:7/10/2014)... journal PNAS (Proceedings of the National Academy of ... sleep deprivation have a significant effect on our metabolism. ... best time of day to test for diseases such ... effectively. , Researchers from the University of Surrey and ... between sleep deprivation, body clock disruption and metabolism, and ...
(Date:7/10/2014)... 1960s, theatergoers have shelled out for crude 3-D ... their viewing experience. These basic devices, used to ... reality, may soon be rendered obsolete with the ... Aviv University researchers. , TAU doctoral students Yuval ... highly efficient holography based on nanoantennas that could ...
Breaking Biology Technology:Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4International Photonic Integrated Circuit (Monolithic Integration, Hybrid Integration, Module Integration) Market - Forecasts to 2019 2Time of day crucial to accurately test for diseases, new research finds 2Projecting a 3-dimensional future 2Projecting a 3-dimensional future 3
... Aug. 14 Transgenomic, Inc. (the,"Company") (OTC Bulletin Board: ... 30, 2007. The Company,s financial results are,presented in the ... Company reported a net profit of $0.2 million or ... compared to a net loss of $0.4 million or,$0.01 ...
... Genetics, Inc.,(Nasdaq: RGDX ), today reported financial ... "The second quarter of 2007 was very ... public offering in June," said,Kathleen Danenberg, President and ... the recent developments that have since been announced. ...
... Summertime equals fun for a lot of,folks. ... (IBS), typical,summer fare could also mean aggravating their ... for IBS," has more on,what people with IBS ... IBS from,ruining their celebrations. Listen to this ...
Cached Biology Technology:Transgenomic, Inc. Reports Second Quarter 2007 Results 2Transgenomic, Inc. Reports Second Quarter 2007 Results 3Transgenomic, Inc. Reports Second Quarter 2007 Results 4Transgenomic, Inc. Reports Second Quarter 2007 Results 5Transgenomic, Inc. Reports Second Quarter 2007 Results 6Transgenomic, Inc. Reports Second Quarter 2007 Results 7Transgenomic, Inc. Reports Second Quarter 2007 Results 8Response Genetics Reports Second Quarter 2007 Financial Results 2Response Genetics Reports Second Quarter 2007 Financial Results 3Response Genetics Reports Second Quarter 2007 Financial Results 4Response Genetics Reports Second Quarter 2007 Financial Results 5Response Genetics Reports Second Quarter 2007 Financial Results 6Response Genetics Reports Second Quarter 2007 Financial Results 7Response Genetics Reports Second Quarter 2007 Financial Results 8
(Date:7/10/2014)... Florida , July 1, 2014 ... pave way for convenience and improved security: NXT-ID, Inc. (OTCBB: ... (NASDAQ: GOOG ), Apple Inc. (NASDAQ: ... MasterCard Corporation (NYSE: MA) NXT-ID, Inc., (OTCQB: NXTD) a ... pleased to announce that the second series of 30 second ...
(Date:7/10/2014)... 2014 It is a great honor for ... of the world-renowned Thoracic and Cardiovascular surgeon, Mark E ... Dr. Ginsburg, with over 34 years of experience, is ... Good Samaritan Regional Medical Center. Dr. Ginsburg has been ... and is considered an expert in the implantation of ...
(Date:7/10/2014)... -- According to the new market research ... Material (Optical Prism, Pizeoelectric, Capacitive, and Adhesives), Application (Mobile ... Finance), and Geography - Global Trends & Forecasts to ... Sensors Market is projected to cross $14.35 Billion by ... 2014 to 2020. Browse more than 78 ...
Breaking Biology News(10 mins):Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 2Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 3Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 4Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 5Avery Biomedical Devices, Inc. announces the appointment of Mark E Ginsburg, M.D. to its Board of Directors 2Fingerprint Sensors Market worth $14.35 Billion by 2020 2Fingerprint Sensors Market worth $14.35 Billion by 2020 3
... Researchers at Burnham Institute for Medical Research at ... (a chain of amino acids) that specifically recognizes and ... was also shown to deliver diagnostic particles and medicines ... dramatically enhance both cancer detection and treatment. The work ...
... Mass. December 7, 2009 Biogen Idec (NASDAQ: ... fumarate) achieved key milestones in clinical trials for multiple ... the last patient was enrolled in the CONFIRM trial, ... evaluate the efficacy and safety of BG-12 as a ...
... Researchers from Yale University and Mirna Therapeutics, Inc., reversed ... occurring tumor suppressor microRNA. The study reveals that a ... role in cancer treatment, and provides hope for future patients ... cancers. "This is the first time anybody has shown a ...
Cached Biology News:Delivering medicine directly into a tumor 2Biogen Idec's oral compound BG-12 achieves development milestones in MS and RA 2
Request Info...
Human Osteocalcin (1-22) mature form. Also reacts with Osteocalcin (1-44) and Osteocalcin (1-49). No reactivity with Bone sialoprotein....
TGF-beta 1,-2,-3 MAb (Clone 1D11)...
1/4" to 1/8" Adapter for Reflectance Probe Holder...
Biology Products: